Phase I study of combination of pasireotide (SOM 230) plus gemcitabine in metastatic pancreatic cancer (MPC).
Richard D. Kim
Research Funding - Novartis
Helen Jump
No relevant relationships to disclose
Dung-Tsa Chen
No relevant relationships to disclose
William J. Fulp
No relevant relationships to disclose
David Shibata
No relevant relationships to disclose
Erin Siegel
No relevant relationships to disclose
Gregory M. Springett
No relevant relationships to disclose